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INTRODUCTION
The Centre for Diagnostic Nuclear Imaging (CDNI) of Universiti Putra Malaysia (UPM) is 
equipped with a Siemens® Biograph 64 True-V Positron Emission Tomography (PET)/Computed 
Tomography (CT) scanner (Germany) operating on a 64-multislice CT detector system. This 
Siemens® Biograph 64 system has the latest technology of lutetium oxyorthosilicate (LSO) 
for its camera detector. LSO offers greater sensitivity and improves dead time and counting 
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A shift to administration of optimal dose of 18F-FDG between 4 and 5 MBq/kg from the current practice 
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MIP images of 32 patients (23 men, 9 women, age 51.9 ± 13.7 years), administered with 18F-FDG 
(activity 5.3 ± 0.5 MBq/kg, 45 minutes uptake time) for whole-body PET/CT examinations, were 
evaluated. Image quality was assessed visually by two radiologists using a three-point scoring scale: 
poor, reasonable and excellent. The interobserver agreement revealed a kappa value higher than 0.7. 
Therefore, the utilisation of 18F-FDG dose between 4 and 5MBq/kg is considered an optimum dose for 
whole-body PET/CT examination.
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rate performance, which allow it to handle 
even very high activity levels as compared to 
traditional bismuth germanate (BGO) detector 
(Nagasaki et al., 2011; Everaert et al., 2003; 
Nutt, 2002).
However, the recommended doses of 
18F-FDG are inconsistent among countries 
due to facility setup, protocol and patient 
Hishar Hassan, Salasiah Mustafa, Fathinul Fikri Ahmad Saad and Abdul Jalil Nordin
188 Pertanika J. Sci. & Technol. 23 (2): 187 - 192 (2015)
factors. Although the current practice in CDNI employs the administration of 18F-FDG dose 
between 6 and 8 MBq/kg,the author reiterates that, with a greater sensitivity of LSO camera 
detector equipped in PET/CT system at CDNI, an optimal dose of 18F-FDG between 4 and 5 
MBq/kg administered to the patient is sufficient to achieve a reasonable-to-excellent image 
quality without compromising the medical diagnostic aspect. Interestingly, dose optimisation 
of 18F-FDG has been proven to significantly reduce the total effective dose received by patients 
undergoing PET/CT examination and also technologists during the dose preparation.
MATERIALS AND METHODS
Patient Preparation and Administration of 18F-FDG
A total of 32 patients were recruited in this study. Prior toundergoing the PET/CT whole-body 
examination,patients were required to fast for at least 6 hours before the scheduled appointment 
time. Upon admission at the centre, the patients’ body weight and height were taken (average 
of 61.7 ± 6.2 kg, BMI averaged, 22.7 ± 1.2 kg/m2) and blood glucose level (average, 5.10 ± 
0.9 mmol/L) was recorded in their respective examination forms. Nonetheless, patients with 
hyper or hypoglycaemia conditions were excluded from the study to eliminate any possible 
bias on the uptake of 18F-FDG. The patients were then briefed by a radiologist on the complete 
procedure and also possible adverse effects prior to giving and signing an informed consent.
18F-FDG dose ranging from 4 MBq to 5 MBq/kg (average of 5.3 ± 0.5 MBq/kg), which 
had been prepared in the hot laboratory, was intravenously administered to the patients. The 
dose prepared was lower than the usual practice as to prove that a lower dose of 18F-FDG was 
sufficient to yield a reasonable-to-excellent image quality. The total dose given was calculated 
in accordance to the patients’ body weight. Then, the patients were asked to lie down on a bed 
in a dimly lit room for approximately 45 minutes to minimise brain and muscle stimulations 
during the 18F-FDG uptake.
Image Acquisition
Quality Assurance and Quality Control of PET/CT Scanner
Routine quality control procedures were performed by a radiographer on the PET/CT scanner 
in accordance to IAEA Human Health Series No. 1, Quality Assurance for PET and PET/CT 
Systems prior to the examination. This was to ensure that the system was operated within the 
tolerance level without affecting the image quality of PET/CT, patients’ dose of CT, accuracy 
of CT-based attenuation corrections and accuracy of CT and PET co-registration (IAEA 2009).
Imaging Protocol
Following the 45-minute uptake time, the patients were brought to the PET/CT suite. The 
radiographer assisted the patients during the procedure. The patients were positioned with 
their arms above the head, lying supine on the scanning table throughout the examination. 
A low dose (150 mAs, 120 kVp) axial CT topogram scan was performed from the base of 
skull to the mid-thigh region using a modulated 4D care dose system for the purpose of study 
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planning. An Optivantage™ dual head injector was used to deliver about 80 to 100 ml of 
contrast (Omnipaque), with the delivery rate set at 2 to 3 ml per second. This was done to 
encourage renal excretion and enhance the contrast of structures or fluids in the body for the 
purpose of diagnostic imaging.
Upon completion of the CT image acquisition, the second phase of the study was 
commenced with PET image acquisition. The PET images were acquired in 3-dimensional 
(3D) mode on all patients in 5 different bed positions at 2 minutes per bed position. At the end 
of the examination procedure, all the images were reconstructed using the iterative algorithm 
technique. CT data fused to PET data was used for attenuation correction of the PET images. 
Meanwhile, a3D maximum intensity projection (MIP) and 2D multiplanar image in axial, 
coronal and sagittal were made available for reviewing. Each of the 3D MIP images of the 32 
study subjects were then analysed and scored visually using a 3-score system: poor, reasonable 
and excellent by two nuclear radiologists.
Statistical Analysis
The interobserver of the agreement between two nuclear radiologists was evaluated using kappa 
measure of agreement (K). Kappa values of >0.8 indicate almost perfect agreement while kappa 
values of 0.61 to 0.80 indicate substantial agreement (Viera et al., 2005). 
RESULTS
Patients’ body weight was recorded and an average of 61.7 ± 6.2 kg was attained, with average 
BMI value of 22.7 ± 1.2 kg/m2 and average blood glucose level of 5.10 ± 0.9 mmol/L.
The visual analysis of MIP PET images for each of the image was given the scores of 
“excellent”, “reasonable” and “poor”, as shown in Fig.1.
As observed in Figures 1(e) and (f), the MIP images were considered as excellent by nuclear 
radiologists based on the low background noise to the image sharpness and the intensity of 
18F-FDG in the organ of interest: the brain, liver and urinary bladder. In contrast to Figures 1(a) 
and (b), the region of interest drawn was rather faint. Meanwhile, the MIP images of 1(a) and 
1(b) were from the patients who had been administered with 18F-FDG doses at 6 to 8MBq/kg.
“Poor” “Reasonable” “Excellent”
(a) F, 54 yr old, 
**6.35 MBq/kg
(b) M, 51 yr old, 
**7.60 MBq/kg
(c) F, 50 yr old, 
4.67 MBq/kg
(d) M, 47 yr old, 
4.59 MBq/kg
(e) M, 48 yr old, 
4.97 MBq/kg
(f) F, 65 yr old, 
4.75 MBq/kg)
Fig.1: Representative MIP whole body PET/CT images quality scoring system
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The cross tabulation of the visual analysis scores of PET image quality given by two 
nuclear radiologists in relation to the activity administered per kg of body weight of 18F-FDG 
is summarised in Table 1.
TABLE 1 : Cross Tabulation on Interobserver Agreement of Visual Analysis Scores of PET Scan Image 
Quality in Relation to Administered Activity of 18F-FDG (4 to 5 MBq/kg)
The tabulated scores of the PET image quality presented in Table 1 show that out of the 32 
images analysed by two nuclear radiologists, 30 images (94%) were classified as reasonable 
and excellent by Nuclear Radiologist 1 as compared with only 29 images (91%) by Nuclear 
Radiologist 2. The interobserver agreement between the two nuclear radiologists on the PET 
image scoring was evaluated in the statistical analysis using the kappa measure of agreement 
(K). The agreement between the two nuclear radiologists for the complete group of PET image 
quality was apparently substantial, with a kappa value of 0.709 (p < 0.05).
DISCUSSION
A shift to an optimum dose by means of lowering the current dose practice from 6-8 MBq/
kg to 4-5 MBq/kg could also potentially yield a reasonable-to-excellent PET/CT image. It 
is known that the uptake time period, patient’s blood glucose level, patient motion, patient 
comfort and inflammation are the biological and physical factors that attribute to the estimation 
of standardise uptake value (SUV) and image quality (Boellaard et al.,2008). In this study, 
however, the researchers ensured that all the above-mentioned factors were minimised and 
controlled to reduce any potential statistical bias.
Referring to Fig.1, the “gold standard” of characterising the excellent quality of the PET 
image is by looking at the sharp contrast between the organs of interest (brain, liver and urinary 
bladder) and the low level of background noise (Everaert et al.,2003). As observed in Figures 
1(e) and (f), the intensity of 18F-FDG in structures of organ or interest appeared to be sharp 
and homogenous.
The interobserver agreement on the PET images from both the nuclear radiologists in the 
form of kappa value, 0.709 (p < 0.05), revealed the interobserver agreement was substantially 
good. This finding indicates a good level of agreement during the independent assessment on 
PET image (Viera et al.,2005). As the assessment of the PET image quality given the 18F-FDG 
dose at 4 to 5 MBq/kg revealed a reasonable-to-excellent quality image, it is recommended 
that a shift from the current practice of 6-8 MBq/kg to 4-5 MBq/kg of 18F-FDG dose be 
administered to patients.
Cross tabulation on visual analysis scores of PET image quality 
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 1 Image quality
Nuclear Radiologist 2
Total
Poor Reasonable Excellent
Poor 2 0 0 2
Reasonable 1 8 3 12
Excellent 0 1 17 18
Total 3 9 20 32
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Moreover, this recommended low dose is also in compliance with the recommendation 
by the International Commission on Radiological Protection (ICRP) on dose optimisation 
(Hishar et al., 2014; Hishar et al., 2013; Everaert et al., 2003). Lowering the current practice 
dose would directly reduce the effective dose (internal exposure) received by the patients. 
The effective dose for 18F-FDG is calculated via the amount of radioactivity administered and 
the entrance exposure (IAEA 2008). The effective dose of internal exposure from intravenous 
administration of an 18F-FDG activity can be estimated from Eint = Г. A, where Г is dose 
coefficient (18F = 19 µSv/MBq) and A is the administered activity (ICRP 1999). With the 
suggested dose administration of 4 MBq/kg compared to the current dose practice of 8 MBq/
kg, the effective dose received by the patients would be reduced by half.
As shown in Fig.1, even at 4 MBq/kg the 18F-FDG dose has yielded a reasonable-to-
excellent image; therefore, the current practice of giving more than 4 MBq/kg to patients 
should be questioned. Even though some might refute that the radiation exposure received 
by the patient is outweighed by its justified benefit for medical diagnostic purpose, it is still 
notright to do so when a better and safer solution does exist. In addition, this approach will also 
help to reduce the radiation burden, not only to the patient but also to the personnel involved 
during the preparation of 18F-FDG dose.
As for the expenditure aspect, the operational cost will be greatly reduced because CDNI 
purchases the 18F-FDG dose from the suppliers in the market. This is due to the optimal dose 
that will be adjusted, which may directly influence the purchase of 18F-FDG compound. With 
the optimal dose suggested, the author foresees that the operational cost (particularly the 
expenditure on 18F-FDG purchase) will be reduced by at least 10 to 15 %. The author is also 
confident that with the dose suggested, together with the efficiency in the management of 
patients (patient’s scheduling and proper scanning plan), there is no doubt that the operational 
cost of CDNI will be reduced with the added benefit of reduced radiation exposure to the 
patients and staff.
Limitations of the study
A limitation of this current study is the small number of patients involved as its sample, with 
only 32 images analysed. The study was intended to be a preliminary study to prove that with an 
LSO camera detector of greater sensitivity equipped in PET/CT system at CDNI, 18F-FDG dose 
activity ranging between 4 and 5 MBq/kg is sufficient for a PET/CT whole–body examination. 
Thus, the extent of the study may be conducted using a larger number of patients in the future.
CONCLUSION
This short communication is to suggest the implementation of 18F-FDG dose between 4 and 5 
MBq/kg for standard diagnostic whole-body PET/CT scans. This preliminary study revealed 
that the recommended lower dose of 18F-FDG activity is able to yield satisfactory image quality, 
which does not compromise the diagnostic ability of the test and radiation protection benefits 
nor incur any additional cost.
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